Showing 1 of 1 PublicationsType 2 diabetes therapyMayerson AB, Inzucchi SE. Type 2 diabetes therapy. Postgraduate Medicine 2002, 111: 83-95. PMID: 11912999, DOI: 10.3810/pgm.2002.03.1140.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsMeSH Keywords and ConceptsMeSH KeywordsAlpha-GlucosidasesBenzamidesBiguanidesDiabetes Mellitus, Type 2HumansHypoglycemic AgentsSulfonylurea CompoundsThiazolesThiazolidinedionesConceptsType 2 diabetes therapySide effect profileOral antidiabetic agentsType 2 diabetesMechanism of actionNonglycemic benefitsOral agentsGlycemic controlEffect profileIndividual patientsAntidiabetic agentsDiabetes therapyBetter drugsPatientsAgentsDiabetesTherapyPhysiciansDramatic increaseDownload Full List
Type 2 diabetes therapyMayerson AB, Inzucchi SE. Type 2 diabetes therapy. Postgraduate Medicine 2002, 111: 83-95. PMID: 11912999, DOI: 10.3810/pgm.2002.03.1140.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsMeSH Keywords and ConceptsMeSH KeywordsAlpha-GlucosidasesBenzamidesBiguanidesDiabetes Mellitus, Type 2HumansHypoglycemic AgentsSulfonylurea CompoundsThiazolesThiazolidinedionesConceptsType 2 diabetes therapySide effect profileOral antidiabetic agentsType 2 diabetesMechanism of actionNonglycemic benefitsOral agentsGlycemic controlEffect profileIndividual patientsAntidiabetic agentsDiabetes therapyBetter drugsPatientsAgentsDiabetesTherapyPhysiciansDramatic increase